Medtronic's MiniMed Swap Hits the Home Stretch as Four Regulatory Wins Land

Medtronic shares closed at EUR 78.44, up 2.2%, as MiniMed data landed and a swap offer for up to 225.4 million unit shares nears its October 9 expiry.

Medtronic shares are riding a broader market tailwind, but the medical technology giant has plenty of its own news to digest. The stock added 2.2% on Monday to close at EUR 78.44, a move that media reports attributed to a generally friendly trading environment rather than any single company-specific catalyst. A separate reading of the same session put the gain at 2.1% with a close of EUR 78.36.

What the tape doesn't capture is the sheer volume of clinical and regulatory news flowing out of the company's vascular and cardiac units — and a corporate restructuring that is now entering its decisive phase.

Six-Month Data Bolster the Diabetes Spin-Off Case

MiniMed, the diabetes unit whose separation was set in motion roughly three weeks ago, released six-month study results on Monday. When patients responded more frequently to Smart-MDI system alerts, time spent in the glycemic target range improved by 8.1 percentage points. Average HbA1c values fell by 0.6 percentage points over the same period.

Those figures land at a sensitive moment. The spin-off has weighed on the stock since its announcement, with the shares showing a 3.6% decline in the intervening weeks.

VenaSeal Data Debut at VEINS Congress

Fresh prospective results from the VenaSeal Spectrum program were presented on October 3 at the VEINS Congress 2026. The data cover 24-month outcomes from a 125-patient study examining treatment of advanced chronic venous disease.

A Cluster of Clearances Dated September 30

Medtronic's cardiology and vascular portfolio advanced on several fronts on a single day. The FDA granted clearance and European regulators awarded CE marking for the Affera Prism-2 mapping software. The PulseSelect ProxBox adapter, paired with proximity-indication software, picked up its CE mark at the same time.

The FDA also handed breakthrough device designation to the IN.PACT BTK drug-coated balloon catheter that day. A randomized global approval study of roughly 400 patients is planned to evaluate the treatment, with the designation aimed at speeding development and regulatory review.

Reimbursement Upgrade — With a Long Fuse

The American Medical Association approved new Category I CPT billing codes for two systems, Medtronic announced on October 1. The codes cover the Altaviva implantable tibial neuromodulation device and the Symplicity Spyral renal denervation system, replacing their previous Category III classifications. The catch: they do not take effect until January 2028, leaving reimbursement at existing levels in the interim and ruling out any near-term revenue pop from the upgrade.

Analyst Backing and a Deadline on the Horizon

RBC Capital reaffirmed its Buy rating on October 1 with a price target of $118, lending support to the strategic direction. A smooth execution of the portfolio measures could free up resources for higher-return growth areas.

The most immediate test comes from the exchange offer tied to the MiniMed separation. Medtronic has specified the swap of up to 225,361,295 MiniMed shares held by the parent against outstanding Medtronic stock, detailed in mandatory Rule 425 filings. According to company statements, the offer is set to expire on October 9 unless it is extended or terminated. How investors receive that deadline will shape the next leg of the restructuring story.

With a market capitalization of EUR 98.13 billion, Medtronic remains one of the heavyweights of the global medical technology sector. The regulatory milestones strengthen its profile in vascular and cardiac care, but the gap between a clearance and broad clinical adoption is often wide. Sales execution will determine whether the pipeline translates into meaningful organic growth — and whether the current momentum holds.

Fortune offered its own endorsement in late September, naming Medtronic to its "Change the World" list for 2026 on September 29. The recognition cited the Touch Surgery surgical ecosystem and the Healthy Neighbor program run through Medtronic LABS.